For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Header Divider

Scientific Program

FP611

3627

Dr.SHUBHANGI TANAJI SHEVALE
Membership No Author Name Email Mobile
3627 Dr.SHUBHANGI TANAJI SHEVALE [email protected] 9987602209
Refractive Surgery

Long Term Visual And Refractive Outcomes Of Eyecryl® Phakic IOL For High Myopia & Myopic Astigmatism

Purpose:To evaluate the long term outcomes of Eyecryl phakic IOL (pIOL) for high myopia and myopic astigmatism.
Methods:Electronic Medical records of patients with Eyecryl pIOL or Eyecryl phakic Toric IOL(EPTIOL) from Aug 2017 to July 2022 were retrospectively reviewed.
Results:A total of 186 eyes from 106 patients were analysed.Thirty three spherical and 153 EPTIOL were implanted.Mean follow up was 37.04±13.60 months.The pre-op sphere, cylinder, SE reduced from -9.91 ±5.22 D, -1.67±1.15 D & -10.75 ± 5.35 D to -0.03± 0.29D, -0.09± 0.32D, -0.07 ± 0.35D respectively(p-value>0.05). The mean efficacy & safety indices were 1.02 and 1.01 respectively. The mean vault was 497.86±167.75µ at 2 weeks, which reduced to 481.49±162.07 µ at 3.08 years,( p- <0.001). Endothelial cell loss was 2.4 % in the first 12 months.Two eyes of EPTIOL required realignment.
Conclusion: Eyecryl pIOL implantation was found to be safe and effective surgical procedure for correction of high myopia & myopic astigmatism.

Membership No Author Name Email Mobile
2404 Dr.Sheetal Maharishi [email protected] 9591002092
262 Dr.Sri Ganesh [email protected] 9845129740